Gene And Cell Therapies In Asia: Indian Environment Evolving But Multiple Issues Unresolved

India has taken strides towards creating a supportive environment for its nascent gene therapy research, but the R&D and regulatory infrastructure is still evolving amid concerns over potential product costs.

India has seen an uptick in activity in gene therapy research over the past few years, with researchers more recently experimenting with the gene-editing tool CRISPR-Cas9, though for the most part things appear to be still evolving in the sector, amid lingering concerns around safety and ethical aspects.

Though the exact number of Indian institutes/firms currently engaged in gene therapy research is not easy to ascertain, previous studies and reviews have highlighted some like the Advanced Centre for Treatment, Research and Education for Cancer (ACTREC) in Mumbai, which is involved in gene therapy studies including in head and neck cancer using viral

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

21 May 2025

• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

20 May 2025

• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

20 May 2025

• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

21 May 2025

• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.